Johnson & Johnson Invests Over $1 Billion in New Cell Therapy Manufacturing Facility
Introduction
Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The new site will expand the company’s manufacturing capacity in the United States and support its growing portfolio of advanced medicines for cancer, immune-related conditions and neurological diseases.
Features
The facility will use modern manufacturing technologies designed for next-generation cell therapies.
These treatments are an important part of the company’s pipeline of innovative medicines.
The project is expected to create more than 4,000 construction jobs during the development phase. Once operational, the site will support over 500 skilled roles in biomanufacturing.
It operates ten facilities in the state, covering more than two million square feet across manufacturing, research, distribution and office functions.
The new site will include investment in training to ensure employees are equipped with the skills required for advanced biomanufacturing technologies.
The company has not confirmed an exact completion date. However, the investment is part of its broader U.S. expansion plan scheduled through early 2029.
Specifications:
| Name | Johnson & Johnson |
| Budget | $1 Billion |
| Type | Expansion |
| Year of Completion | 2029 |
